Sysmex Inostics
Aaron J. Lizee boasts extensive experience in commercial operations and business development within the biotechnology and genomics sectors. Currently serving as Vice President of Commercial Operations at Sysmex Inostics, Aaron has previously held key roles such as Senior Director of Biopharma Business Development at QIAGEN and Director of Sales at Edico Genome. Aaron's career also includes positions at Codexis, Inc. and QIAGEN, where roles spanned from Associate Director of Global Marketing to Sales Development Manager. Aaron holds a Bachelor of Science degree in Business Administration with a Marketing focus from Eastern Connecticut State University and an Associate of Science degree in Architectural Design Technology from CT State Three Rivers.
This person is not in any offices
Sysmex Inostics
Leaders of the Global Liquid Biopsy Revolution As pioneers in blood-based cell-free tumor DNA (ctDNA) mutation detection, Sysmex Inostics has provided custom assays and CLIA-certified lab services to leading BioPharma companies over the last 10 years with the overall goal: to develop therapeutics that extend lives and provide diagnostics to monitor response to therapy, identify targetable resistance alterations, and detect minimal residual disease (MRD). SafeSEQ NGS technology can detect clinically relevant mutations in circulating tumor DNA (ctDNA) with robust detection as low as 0.03% mutant allele frequency (MAF), thus ensuring reliable molecular information for real-time therapy selection as well as monitoring of tumor response from across a broader range of genomic regions.